‘Pharma Bro’ Martin Shkreli wins proxy battle from prison

A group of activist investors seeking to wrest control of Martin Shkreli’s pharmaceutical company failed miserably this week — with the “Pharma Bro” voting his shares from prison.

But the battle is not over, and the investors now plan to seize Shkreli’s 44 percent stake in Phoenixus – the parent of Shkreli’s Turing Pharmaceuticals, now renamed Vyera, The Post has learned. On Monday, former Shkreli confidante and Vyera executive Kevin Mulleady, together with Jason Aryeh, a longtime activist investor in the pharmaceutical industry, held a special meeting asking Phoenixus shareholders to replace the current board of directors, who they say are Shkreli cronies.